Seres Therapeutics, Inc. (MCRB)
NMS – Real Time Price. Currency in USD
4.64
0.00 (0.00%)
Market open: Aug 12, 2026, 10:55 AM EDT
4.68
+0.04 (0.86%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
Find any stock by ticker or company name

NMS – Real Time Price. Currency in USD
4.64
0.00 (0.00%)
Market open: Aug 12, 2026, 10:55 AM EDT
4.68
+0.04 (0.86%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
No Data
There are no news for this stock.
Total debt $56.6M significantly exceeds cash reserves ($15.6M), raising financial stability concerns
Total current assets $42.3M exceed Total current liabilities $20.0M, highlighting excellent liquidity
Debt-to-equity ratio (1.6) far exceeds the industry average, reflecting over-leverage
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$22.4M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 2.11 | 6.05 | 10 | |
| Quick ratio | 2.11 | 5.63 | 10 | |
| Debt to Equity | 1.64 | 0.30 | 4.0 | |
| Debt to Assets | 0.56 | 1.04 | 4.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 5.8 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 7M | N/A | N/A | 789K | 2M |
| Gross Profit | -5M | -15M | -15M | -3M | -2M |
| Operating Income | -245M | -195M | -118M | -94M | -77M |
| Net Income | -250M | -114M | -147M | 6M | -22M |
| EBITDA | -234M | -180M | -103M | -90M | -74M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 1709.12 | -206.91 | 5.5 |
| Next quarter | N/A | 42.98 | 5.5 |
| Current year | 1648.67 | -649.22 | 5.5 |
| Next year | -98.02 | -40.68 | 1.0 |
| Weighted average score | 4.4 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 105.59 | 123.01 | 122.6 | -36.87 | 7.8 |
| Y/Y | 999 | 123.07 | 120.7 | -66.24 | 7.8 |
| 3y average | 632.67 | 43.19 | 386.82 | 43.06 | 10 |
| 5y average | 427.85 | -25.08 | 195.07 | -1593.12 | 5.5 |
| Weighted average score | 7.8 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |